MARKET

MESO

MESO

Mesoblast
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.94
-0.06
-0.67%
After Hours: 9.00 +0.06 +0.67% 18:56 04/16 EDT
OPEN
8.94
PREV CLOSE
9.00
HIGH
9.11
LOW
8.77
VOLUME
74.66K
TURNOVER
--
52 WEEK HIGH
21.28
52 WEEK LOW
6.09
MARKET CAP
1.05B
P/E (TTM)
-10.1591
1D
5D
1M
3M
1Y
5Y
Stem Cell Therapy Market Business Scenario, Size, Share, Growth, Insights, Industry Analysis, Trends and Forecasts Report 2027
Apr 16, 2021 (Market Insight Reports) -- The global Stem Cell Therapy Market is expected to reach USD 3,693.6 Million by 2027, according to a new report by...
Market Insight Reports · 1d ago
Tissue Regeneration Market Research Report by Type, by Distribution Channel – Global Forecast to 2025 – Cumulative Impact of COVID-19
Apr 15, 2021 (Heraldkeepers) -- The is Global Tissue Regeneration Market expected to exceed more than US$ 109.0 Billion by 2024 at a CAGR of 34.5% in the...
Heraldkeepers · 2d ago
Bone Graft and Substitutes Market 2020-2027, Growing Demand, Geographical Segmentation, Analysis of Leading Players Ace Surgical Supply Co., Inc., NovaBone Product, LLC., Exactech, Inc., Medtronic Plc., LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation
Apr 14, 2021 (Market Insight Reports) -- “Final Report will add the analysis of the impact of COVID-19 on this industry.” Bone Graft and Substitutes Market...
Market Insight Reports · 3d ago
Adult Stem Cells Market Size 2021 Growing Rapidly with Recent Developments, Industry Share, Trends, Demand, Revenue, Key Findings, Latest Technology, Industry Expansion Strategies till 2026
Apr 13, 2021 (The Expresswire) -- The Global “Adult Stem Cells Market” 2021 research report is a historical overview and in-depth study on the current and...
The Express Wire · 3d ago
Cell Therapy Market projected to reach US$ 12,563.23 million by 2027 and to grow at a CAGR of 7.2%
Apr 09, 2021 (AB Digital via COMTEX) -- According to our new market research study on “Cell Therapy Market Forecast to 2027 – COVID-19 Impact and...
ABNewswire · 04/09 19:57
global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030
New York, April 09, Apr 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/09 10:11
Stem Cell Therapy Market Manufacturers, type, Application, Development, Expansion, Merger, Acquisition, New Product Launches, Global Industry Analysis Report by 2027
Market Insight Reports · 04/08 12:12
Analysts’ Top Healthcare Picks: Mesoblast (MESO)
Analysts fell to the sidelines weighing in on and Mesoblast (MESO) with neutral ratings, indicating that the experts are neither bullish nor bearish on
SmarterAnalyst · 04/08 09:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MESO. Analyze the recent business situations of Mesoblast through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MESO stock price target is 14.42 with a high estimate of 23.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 3.03M
% Owned: 2.58%
Shares Outstanding: 117.40M
TypeInstitutionsShares
Increased
13
376.68K
New
12
163.96K
Decreased
16
447.41K
Sold Out
12
490.05K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Swedish
Chief Executive Officer/Executive Director
Silviu Itescu
Vice Chairman/Non-Executive Independent Director
William Burns
Chief Financial Officer
Joshua Muntner
Chief Operating Officer
Dagmar Rosa-Bjorkeson
Senior Vice President
Eric Strati
General Counsel
Peter Howard
Other
Fred Grossman
Other
John McMannis
Other
Paul Simmons
Other
Geraldine Storton
Secretary
Charlie Harrison
Secretary
Niva Sivakumar
Director
Philip Facchina
Non-Executive Independent Director
Donal O'Dwyer
Non-Executive Independent Director
Eric Rose
Non-Executive Independent Director
Michael Spooner
Non-Executive Independent Director
Shawn Tomasello
No Data
  • All
  • Financials
  • Insiders
More
About MESO
Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.

Webull offers kinds of Mesoblast limited (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.